Weisz G, Lavy A, Adir Y, Melamed Y, Rubin D, Eidelman S, Pollack S, et al.
Journal of clinical immunology. Date of publication 1997 Mar 1;volume 17(2):154-9.
1. J Clin Immunol. 1997 Mar;17(2):154-9.
Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by
circulating monocytes during hyperbaric oxygen treatment in patients with
perianal Crohn's disease.
Weisz G(1), Lavy A, Adir Y, Melamed Y, Rubin D, Eidelman S, Pollack S.
Author information:
(1)Israeli Naval Hyperbaric Institute, Rambam Medical Center, Haifa, Israel.
Treatment of perianal inflammatory lesions in Crohn's disease (CD) is
unsatisfactory and novel treatment modalities are pursued. We have recently
reported a good clinical effect of hyperbaric oxygen (HBO) treatment in perianal
CD. In the present study, seven patients with perianal CD were subjected to daily
sessions of HBO in a multiplace hyperbaric chamber. Each patient received a total
of 20 sessions during a time period of 1 month, and IL-1, IL-6, and TNF-alpha
measurements were done several times during the initial sessions and after
completing therapy. Pretreatment cytokine levels were elevated in patients
compared to age-matched 10 normal controls. During the first 7 days of treatment,
IL-1, IL-6, and TNF-alpha levels in supernatants of LPS-stimulated monocytes
derived from patients' peripheral blood were decreased compared to pretreatment
levels. Parallel measurements of serum IL-1 levels revealed an initial elevation
and thereafter decreased levels, which remained low throughout the first week of
HBO treatment. After completion of therapy, cytokine levels increased to
pretreatment values. We conclude that alterations in secretion of IL-1, IL-6, and
TNF-alpha may be related to the good clinical effect of HBO treatment in CD
patients with perianal disease.
DOI: 10.1023/a:1027378532003
PMID: 9083891 [Indexed for MEDLINE]
